

Personalized Stem Cells CEO Presents Clinical Trial Results at Annual IFATS Meeting

CEO and founder of Personalized Stem Cells, Dr. Robert Harman, recently presented clinical trial results at the annual IFATS meeting in Ft. Lauderdale.

POWAY, CALIFORNIA, US, December 8, 2021 /EINPresswire.com/ -- CEO and founder of [Personalized Stem Cells, Inc](#) (PSC), Dr. Robert Harman, recently presented clinical trial results at the annual International Federation for Adipose Therapeutics and Science (IFATS) meeting in Ft. Lauderdale, FL. PSC, an adipose derived stem cell company, completed their first clinical trial in early 2021 and the results were very promising. The FDA approved phase 1/2a clinical trial studied the safety and preliminary efficacy of autologous, adipose derived stem cells for the treatment of knee osteoarthritis.



Dr. Robert Harman,
Founder and CEO of
Personalized Stem
Cells, Inc.

As [announced](#) earlier this year, the clinical trial results were very promising. Safety was the primary objective and there were no serious adverse events reported. The preliminary efficacy results were also positive. Efficacy was measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS) and showed that 79.3% of the patients improved above the “minimal important change” (MIC) with an average improvement over baseline of 2.2 times the MIC. The KOOS measures pain, other symptoms, daily function, sports, and knee related quality of life outcome sub-scales.

Results from PSC’s knee osteoarthritis trial were also presented at The Orthobiologic Institute (TOBI) conference in early October 2021. PSC Medical Director, Dr. Christopher Rogers, delivered an informative talk discussing the safety and efficacy results of the phase 1/2a clinical trial.

PSC plans to launch a phase 2 placebo-controlled knee osteoarthritis trial in the coming months. Additionally, PSC plans to pursue FDA approval for a stem cell clinical trial to treat traumatic brain injury (concussion). Stem cell therapy may provide answers and tools to address the chronic debilitation experienced by TBI victims. Recent studies have found that stem cells have demonstrated the ability to regenerate damaged nerve tissues which may lead to an improvement in disabilities and thereby quality of life.

[About Personalized Stem Cells, Inc.](#)

Personalized Stem Cells was formed in 2018 to advance human regenerative medicine by

securing FDA approval for serious diseases with limited treatment options. This privately held biopharmaceutical enterprise, based near San Diego (California), offers qualified physicians a GMP compliant stem cell product for use in approved clinical trials. PSC has licensed a portfolio of patents and applications in the field of regenerative medicine which includes patents covering treatment of lung diseases including COVID-19.

Kristi Hauta, Marketing
Personalized Stem Cells, Inc
+1 833-772-3557
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/557836737>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.